{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:55:31Z","timestamp":1768294531460,"version":"3.49.0"},"reference-count":143,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T00:00:00Z","timestamp":1328572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Certain drugs used in the treatment of patients with anxiety disorders can interact with other psychotropic drugs and with pharmacological treatments for physical illnesses. There is a need for an updated comparative review of clinically relevant drug interactions in this area.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Relevant literature on drug interactions with medications used in the treatment of anxiety disorders was identified through a search in MEDLINE and EMBASE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Drug interactions involving medications used to treat anxiety disorders may be pharmacokinetic, such as enzyme inhibition or induction in the cytochrome P450 system and transporter\u2010mediated drug interactions, or pharmacodynamic, such as additive effects in causing drowsiness or additive effects at neurotransmitter receptors. Certain selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, and paroxetine) are particularly liable to be potentially involved in untoward pharmacokinetic interactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The potential for drug interactions with medications used in anxiety disorders should be the cause of clinical concern, particularly in elderly individuals. However, the liability for harmful drug interactions may be anticipated, and the risk reduced. Although not all interactions are clinically relevant, careful monitoring of clinical response and possible interactions is essential. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2217","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T09:20:01Z","timestamp":1328606401000},"page":"239-253","source":"Crossref","is-referenced-by-count":36,"title":["Clinically relevant drug interactions in anxiety disorders"],"prefix":"10.1002","volume":"27","author":[{"given":"Maria Rosaria","family":"Muscatello","sequence":"first","affiliation":[{"name":"Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology University of Messina  Messina Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borwin","family":"Bandelow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy University of G\u00f6ttingen  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences Academic Unit, Faculty of Medicine University of Southampton  Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0516"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009903900314"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90013-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199816050-00007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105059253"},{"issue":"9","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S1092852900026924","article-title":"The medical treatment of obsessive\u2013compulsive disorder and anxiety","volume":"13","author":"Bandelow B","year":"2008","journal-title":"CNS Spectr"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90095-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.18"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02763.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25026"},{"key":"e_1_2_8_14_1","first-page":"165","article-title":"Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?","volume":"47","author":"Bonnet P","year":"1992","journal-title":"Therapie"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.03.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1872"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.19204.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70015-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125689.05091.c6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb01306.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.11.1357"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1011"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.6.820"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.123"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344335"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9828-9"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100324"},{"key":"e_1_2_8_29_1","volume-title":"Drug Interactions in Psychiatry","author":"Ciraulo DA","year":"1995"},{"key":"e_1_2_8_30_1","volume-title":"Concise Guide to Drug interaction Principles for Medical Practice: Cytochrome P450s, UG7\u2010s, P\u2010Glycoproteins","author":"Cozza KL","year":"2003"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.1.59"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620020-00005"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.7.795"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_303.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7217.1106"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100713"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03691.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04856blu"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.065607"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.9.1317b"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0894"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91265-3"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199803000-00006"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181e5c095"},{"key":"e_1_2_8_45_1","unstructured":"European Medicines Agency.2011.Pharmacovigilance Working Party (PhVWP) monthly report issue 110. Annex 2: Citalopram\u2014risk of QT interval prolongation. 27th October 2011."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00024"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00195913"},{"key":"e_1_2_8_48_1","first-page":"988","article-title":"Recognition and treatment of serotonin syndrome","volume":"54","author":"Frank C","year":"2008","journal-title":"Can Fam Physician"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb03200.x"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00166-8"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199700321-00007"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.11.016"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707253"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1517"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9428-0"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0404-3"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122009746"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0840-7_24"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.175"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.98"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.08.008"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02251285"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200004000-00006"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890903186168"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023338017"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104788"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181fc50d5"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200210000-00010"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199408000-00011"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb01282.x"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.5.412-a"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199408000-00006"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji005"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02230.x"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c693"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000186869.67418.bc"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199706000-00012"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903575273"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr010"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604533"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004266618"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.10.1152"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.52"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C112"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.1.81"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835050-00003"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614040-00002"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03541.x"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.5647"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.9.942"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200110000-00007"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.026"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.9.1307"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.01801.x"},{"issue":"7","key":"e_1_2_8_95_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900026043","article-title":"Antidepressant drug\u2013drug interactions: clinical relevance and risk management","volume":"12","author":"Nemeroff CB","year":"2007","journal-title":"CNS Spectr"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00007"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.5.595"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03154.x"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(02)00274-8"},{"key":"e_1_2_8_100_1","first-page":"126","article-title":"Interaction of fluoxetine with carbamazepine","volume":"51","author":"Pearson HJ","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.167"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199404000-00002"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200702000-00005"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301070"},{"issue":"1","key":"e_1_2_8_105_1","first-page":"16","article-title":"Absence of a sertraline\u2010mediated effect on digoxin pharmacokinetics and electrocardiographic changes","volume":"57","author":"Rapeport WG","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"e_1_2_8_106_1","first-page":"24","article-title":"Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin","volume":"57","author":"Rapeport WG","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"e_1_2_8_107_1","first-page":"20","article-title":"Absence of sertraline\u2010mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine","volume":"57","author":"Rapeport WG","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120001392"},{"key":"e_1_2_8_109_1","first-page":"173","article-title":"Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients","volume":"51","author":"Repo\u2010Tiihonen E","year":"2005","journal-title":"Neuropsychology"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000185428.02430.c7"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04322.x"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ee2afe"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.102004250.x"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1420"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199412000-00001"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch28"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199805000-00009"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200106000-00007"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199306000-00012"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8361"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200208000-00014"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199206000-00004"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199402060-00008"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.043s2037.x"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80047-1"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg108"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199112000-00019"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0563-9"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979221"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02543.x"},{"key":"e_1_2_8_131_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199801000-00003","article-title":"Co\u2010administration of citalopram and clozapine: effect on plasma clozapine levels","volume":"13","author":"Taylor D","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"e_1_2_8_132_1","volume-title":"Guidance for Industry. Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labelling. Draft Guidance","author":"US Food and Drug Administration","year":"2006"},{"key":"e_1_2_8_133_1","first-page":"1289","article-title":"Toxic effects of theophylline caused by fluvoxamine","volume":"151","author":"Van den Brekel AM","year":"1994","journal-title":"Can Med Assoc J"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1737"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91265-N"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200108000-00015"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046532"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1991.tb03723.x"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199802000-00002"},{"key":"e_1_2_8_140_1","first-page":"19","article-title":"Interaction of phenytoin and fluoxetine","volume":"107","author":"Woods DJ","year":"1994","journal-title":"New Zeal Med J"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6898.241-b"},{"key":"e_1_2_8_142_1","first-page":"480","article-title":"Interaction of fluvoxamine with warfarin in an elderly woman","volume":"40","author":"Yap KB","year":"1999","journal-title":"Singapore Med J"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68306-2"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.359"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2217","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:30:38Z","timestamp":1698636638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,7]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/hup.2217"],"URL":"https:\/\/doi.org\/10.1002\/hup.2217","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,7]]}}}